ASX ANNOUNCEMENT **12 November 2026**

EBR Notifies Customers about Updated Ultrasound Precautions for Patients Implanted with the WiSE® System

Key Highlights

- EBR is notifying healthcare providers about updated diagnostic ultrasound precautions for patients implanted with the WiSE® System.
- This update is consistent with EBR's previous ASX announcement on 16 September 2026, "EBR's FDA plan for addressing echo-induced pacing risks".
- The correction does not require the return, explant, or reprogramming of implanted systems.
- Commercial implants continue without interruption.

Santa Clara, California; 12 November 2026: EBR Systems, Inc. (ASX: "**EBR**", "**EBR Systems**", or the "**Company**"), developer of the world's only wireless cardiac pacing device for heart failure, today announced a medical device correction for the WiSE® System. EBR is providing healthcare professionals with updated safety information and precautions for diagnostic ultrasound imaging, including transthoracic echocardiography (TTE), in patients implanted with the system.

The WiSE System uses ultrasound energy to deliver leadless left ventricular endocardial pacing. Under certain circumstances, externally applied diagnostic ultrasound can cause the implanted electrode to deliver inappropriate pacing.

Through 26 October 2026, EBR identified 17 reported events of ultrasound-induced inappropriate pacing among 586 implanted patients across global clinical, post-market, compassionate-use and commercial experience. One event resulted in death. These figures reflect reports received by EBR and do not represent the probability of an event during an individual TTE examination. Given the high volume of repeat ultrasound exams that heart failure patients typically undergo as part of standard of care, the estimated incidence rate per exam remains low.

No device return, explant, or reprogramming is required. Healthcare professionals should continue routine patient follow-up and device management in accordance with the applicable IFU and follow the imaging precautions whenever TTE is clinically indicated.

John McCutcheon, CEO said:

"Patient safety is our priority. This communication reinforces the precautions healthcare professionals should follow when performing diagnostic ultrasound in patients with WiSE. We are updating our labelling and supporting clinicians in sharing this information across each patient's care team so that the precautions are understood and consistently applied."

Imaging precautions and clinician communication

Factors associated with increased risk of ultrasound induced inappropriate pacing include the first 30 days after electrode implantation, an apical or near-apical electrode location, high Mechanical Index settings, low-frequency ultrasound, and imaging from apical views. The absence of these factors does not eliminate the risk; precautions apply to every TTE examination involving a patient with an implanted WiSE System.

The physician communication directs healthcare professionals to:

- Monitor patients continuously by ECG during diagnostic echocardiography, keep external defibrillation equipment in the room for immediate use, and have a physician immediately available
- Use the lowest power setting that provides a clinically adequate image; avoid prolonged imaging of the electrode and avoid illumination of the Electrode when using continuous wave Doppler
- Immediately remove the probe and discontinue imaging if inappropriate pacing occurs
- Ensure patients are educated to show their WiSE implant card or medical alert bracelet / pendant before medical procedures.

EBR is requesting implanting centres share the communication with personnel involved in diagnostic ultrasound and review scheduling and handoff processes, so the patient's WiSE implant is identified before imaging.

EBR is updating the Instructions for Use and Echo Protocol and will provide them through EBR's electronic labelling resources once available. The Company will continue to monitor clinical experience and communicate important safety information to healthcare professionals.

EBR remains committed to patient safety and post-market surveillance. The Company does not expect that this forthcoming labelling update will have a material effect on its ongoing commercial activities or financial position.

For more information about EBR, please visit https://www.ebrsystemsinc.com/.

Investor Webinar

EBR's senior management team plans to host an investor webinar to discuss this announcement.

The webinar is scheduled for **Thursday 12 November 2026 at 11:30am AEDT (Wednesday 11 November at 4:30pm PST).**

Investors can register for the webinar via the following link:

https://attendee.gotowebinar.com/register/3825925990564868441

After registering, you should receive a confirmation email containing information about joining the webinar.

For more information about EBR, please visit https://www.ebrsystemsinc.com/.

ENDS

This announcement has been authorised for release by the EBR Systems Routine Disclosure Committee, a Committee of the Board of Directors.

For more information, please contact:

Company
Andrew Shute
Chief Corporate Development Officer
P: +44 7730 691421
E: investors@ebrwise.com

Investor Relations
Gabriella Hold
The Capital Network
P: +61 2 7257 7338
E: gaby@thecapitalnetwork.com.au

Julia Maguire
The Capital Network
P: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About EBR Systems

Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially

(WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems' WiSE Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device in most markets and is currently only available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products and achieve broad market adoption including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. These forward-looking statements are based on EBR Systems' current expectations and inherently involve significant risks and uncertainties. EBR Systems' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those risks described in more detail in its most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents on file with the SEC from time to time and available on the SEC's website at www.sec.gov.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's ASX-traded (ASX: EBR) CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.